TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05916781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Participants in steroid tapering group will take MMF+TAC during the first 18 months. After 18 months, participants without lupus flare will randomly stop MMF or TAC.~Participants in steroid maintenance group will take MMF+TAC during the first 24 months. After 24 months, participants without lupus flare will randomly stop MMF or TAC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid
Description: Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months.~Participants in steroid maintenance group will consistently take glucocorticoid for 18 months, and stop the use of glucocorticoid after 18 months if they do not flare.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Participants in steroid tapering group will stop taking glucocorticoid after the first 6 months.~Participants in steroid maintenance group will consistently take glucocorticoid for 18 months, and stop the use of glucocorticoid after 18 months if they do not flare.
Study: NCT05295004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training
Description: Patient will watch a 10 minute video on how to use mindfulness meditation to help with sleep after a total joint replacement procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training
Description: Patient will watch a 10 minute video on how to use mindfulness meditation to help with sleep after a total joint replacement procedure.
Study: NCT05392504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercise
Description: The core stability training consist of three phases

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scroth's Program
Description: The Schroth program include exercises for rotational breathing, spinal elongation, deflexion, stretching, de-rotation, and strengthening
Study: NCT05544188

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Differential diagnostic
Description: Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Differential diagnostic
Description: Physiotherapy aimed at correcting functional pathologies of the musculoskeletal system assessed by differential diagnosis (removal of trigger points, stretching of shortened muscles and mobilization of joint blockages)
Study: NCT05365555

Intervention type: PROCEDURE
Intervention: Fascia Iliaca Compartment Block
Description: Blind technique.

Intervention type: PROCEDURE
Intervention: Femoral Nerve Block
Description: Ultrasound guided.

Intervention type: DRUG
Intervention: Ropivacaine
Description: Ropivacaine dosed according to local guidelines.

Intervention type: DRUG
Intervention: Ropivacaine
Description: Ropivacaine dosed according to local guidelines.
Study: NCT05080049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Patients receive a subcutaneous injection of 40,000 IU of erythropoietin alfa or zêta, repeated weekly until Day 28 (if the hemoglobin level is \<12 g/dl and the patient remains hospitalized).~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the control arm, patients receive a subcutaneous injection of placebo (0.9% NaCl) according to the same schedule.~The study treatments are administered by an open-label nurse. In both groups, before each injection, iron deficiency (defined as reticulocyte Hb \<29 pg, or hepcidin \<41 µg/L, or ferritin \<100 µg/L, or ferritin \<300 µg/L with transferrin saturation \<20%) is treated with intravenous iron infusion (depending on the product available at the center). A restrictive transfusion strategy is recommended as long as the patient remains in the ICU, according to recent recommendations.~Six visits are scheduled: V1 for inclusion and the first injection, V2 at Day 7(±2 days) for the second injection, V3 at Day 14(±2 days) for the third injection, V4 at Day 21(±2 days) for the fourth injection, V5 at Day 28(±2 days) for the fifth injection.
Study: NCT05627544

Intervention type: PROCEDURE
Intervention: Anesthesia management/Hip replacement surgery
Description: The effect of anesthesia management on blood transfusion practices in hip replacement surgeries

Intervention type: PROCEDURE
Intervention: Anesthesia management/Hip replacement surgery
Description: The effect of anesthesia management on blood transfusion practices in hip replacement surgeries

Intervention type: PROCEDURE
Intervention: Demographic data
Description: The effect of demographic data on blood transfusion practices in hip replacement surgeries

Intervention type: PROCEDURE
Intervention: Demographic data
Description: The effect of demographic data on blood transfusion practices in hip replacement surgeries

Intervention type: PROCEDURE
Intervention: Chronic diseases
Description: The effect of chronic diseases on blood transfusion practices in hip replacement surgeries

Intervention type: PROCEDURE
Intervention: Chronic diseases
Description: The effect of chronic diseases on blood transfusion practices in hip replacement surgeries

Intervention type: PROCEDURE
Intervention: Postoperative complication
Description: The effect of blood transfusion applications on postoperative complications in hip replacement surgeries

Intervention type: PROCEDURE
Intervention: Postoperative complication
Description: The effect of blood transfusion applications on postoperative complications in hip replacement surgeries
Study: NCT06378671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General treatment
Description: routine bronchoscopy examination, lavage, and mucosal biopsy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: General treatment
Description: routine bronchoscopy examination, lavage, and mucosal biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy Treatment
Description: local cryotherapy treatment (around the left and right main bronchi, upper trachea, and carina)
Study: NCT04860271

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Acupuncture
Description: Manual acupuncture treatment using different types of needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Acupuncture
Description: Manual acupuncture treatment using different types of needle
Study: NCT05842369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADVOS
Description: Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CVVHD
Description: Modulation of acid-base regulation in patients with acute kidney injury, meta- bolic or mixed acidosis and indication for renal replacement therapy
Study: NCT05860842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Six months of supervised combined exercise training program, consisting of 2 sessions/wk of 75 min each, followed by a six-month period of follow-up. Each session will comprise a 5-min warm-up, 30-min endurance exercise, 30-min resistance exercise, 5-min flexibility and 5-min cool-down.
Study: NCT05561361

Intervention type: PROCEDURE
Intervention: Super selective adrenal artery embolization
Description: Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.

Intervention type: DRUG
Intervention: Spironolactone
Description: Aldosterone receptor antagonists are recommended by guidelines for the treatment of bilateral primary aldosteronism.
Study: NCT06341530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib combined with penpulimab
Description: single arm
Study: NCT05167682

Intervention type: OTHER
Intervention: Prehabilitation program
Description: Patient will be asked to follow to catalog of procedures till surgery. Procedures catalog contains behavioral changes, physical training, nutritional counseling, conditioning of pulmonary function and optimization of drug of underlying diseases.
Study: NCT06241807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Plus Chemotherapy
Description: Patients were assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2 or pemetrexed (for adenocarcinoma), 500mg/m2 plus platinum \[cisplatin, 75 mg/m2; carboplatin, area under the curve, 5\])
Study: NCT04623372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suture
Description: suture by separated knots using a non-absorbable 4.0 wire and application of a dry dressing after the punch skin-biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: directed wound healing
Description: application of a dry dressing without any prior suture after the skin biopsy.
Study: NCT05097144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (fanfilcon A)
Description: Daily wear for one month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (fanfilcon A)
Description: Daily wear for one month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (asmofilcon A)
Description: Daily wear for one month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (asmofilcon A)
Description: Daily wear for one month
Study: NCT06025890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Training.
Description: Based on the modularization of core ability improvement, specific ability improvement and ability strategy acquisition, learning problems and interpersonal relationships, social adaptation; and other programs, sometimes combined with computer-aided cognitive training, parenting behavior management training and/or mindfulness training, aerobic exercise and other intervention forms, can achieve personalized functional training intervention for children. Use brain near-infrared imaging technology to capture multimodal neuroimaging features of young children; use high-precision repetitive transcranial direct current stimulation technology to conduct positive neural enhancement and adjustment training on the target brain area. Based on physical therapy stimulation, neuromodulation improves core symptoms in children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Training.
Description: Based on the modularization of core ability improvement, specific ability improvement and ability strategy acquisition, learning problems and interpersonal relationships, social adaptation; and other programs, sometimes combined with computer-aided cognitive training, parenting behavior management training and/or mindfulness training, aerobic exercise and other intervention forms, can achieve personalized functional training intervention for children. Use brain near-infrared imaging technology to capture multimodal neuroimaging features of young children; use high-precision repetitive transcranial direct current stimulation technology to conduct positive neural enhancement and adjustment training on the target brain area. Based on physical therapy stimulation, neuromodulation improves core symptoms in children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observe.
Description: Children with language disorders and ADHD were recruited at an early age when symptoms first appeared. Professional assessments were conducted to evaluate clinically relevant developmental and cranial nerve function indicators using near-infrared brain imaging technology. Follow-up was conducted for two years, and the outcome indicators were language disorder and attention deficit hyperactivity disorder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observe.
Description: Children with language disorders and ADHD were recruited at an early age when symptoms first appeared. Professional assessments were conducted to evaluate clinically relevant developmental and cranial nerve function indicators using near-infrared brain imaging technology. Follow-up was conducted for two years, and the outcome indicators were language disorder and attention deficit hyperactivity disorder.
Study: NCT05932875

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Training
Description: 4 day per week concurrent exercise training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: 4 day per week concurrent exercise training program
Study: NCT06148987

Intervention type: OTHER
Intervention: Questionnaire
Description: The translation and cultural adaptation of the survey will be conducted according to the guidelines of Beaton et al. Following the Beaton guidelines, the translation and cultural adaptation steps are as follows: 1) The original version of the survey will be translated into Turkish separately by two individuals whose native language is Turkish and who are proficient in English. One translator will be an English linguistics scholar unfamiliar with the concepts and terms, while the other will be a physiotherapist familiar with the concepts and terms; 2) Subsequently, the translations will be merged into a single text by these two translators; 3) The final Turkish version of the survey will be translated back into English by two translators who are unaware of the study; 4) The translations will then be combined by these two translators to create a harmonized and single text; 5) The back-translation and cultural adaptation
Study: NCT06098625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Empagliflozin 25 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin 5 mg Oral Tablet
Description: linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
Study: NCT04778982

Intervention type: DRUG
Intervention: KN026 combined with Palbociclib and Fulvestrant
Description: HR+/HER2-positive MBC will be treated by KN026 20 mg/kg+Palbociclib+fulvestrant 500 mg
Study: NCT05045898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plantar massage
Description: The patients will be given a classical massage, known as Swedish massage, consisting of euflorage and petrissage. While the patient is lying in the supine position, a classical massage will be applied to the plantar face, dorsum and toes of both feet, which will take approximately 20 minutes in total. It will last for 6 weeks, 3 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plantar massage
Description: The patients will be given a classical massage, known as Swedish massage, consisting of euflorage and petrissage. While the patient is lying in the supine position, a classical massage will be applied to the plantar face, dorsum and toes of both feet, which will take approximately 20 minutes in total. It will last for 6 weeks, 3 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: textured insoles
Description: Textured insoles will be prepared in accordance with the principles stated by Waddington et al. in 2003. In the studies of Waddington et al., ethyl vinyl acetate (EVA) textured insoles with 4 hemispherical protrusions per cm² were used. The height of each hemispherical protrusion from the EVA floor is 2 mm; The height of the insoles from the ground is 3 mm.~The textured insoles will be prepared by an orthotic prosthesis center by cutting the EVA layer with the above-mentioned features in accordance with the patient's shoe/home shoe insoles and placing them on the shoe/home shoe insoles. Insoles will be provided free of charge to patients. Patients will be asked to wear their shoes/house shoes with insoles while performing activities inside and outside the home for 6 weeks.
Study: NCT04677673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Modified SOX Chemotherapy regimen A cycle consists of Day 1: Oxaliplatin 100mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 60mg/M2 oral (twice daily) Repeated every 22nd day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curative gastrectomy
Description: Radical gastrectomy with D2 lymph node dissection
Study: NCT05026281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantra analyzer
Description: one additional tube will be collected during the usual blood test at two different time and analyzed by Quantra ®
Study: NCT05453032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn
Description: A neurostimulation decivse that works be generating weak electric current via Electrodes. These electrodes placed on a specific cerebral location, where the defect assumed to be there) to modulate the neuronal activity. This neuronal modulation does not induce or fire action potential but it facilitate action potentials and cerebral interconnection as well corticolimbic connection)
Study: NCT04712396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Subects will be administered single doses of capiversatib on Day 1 and Day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will be administered itraconazole twice daily on Day 3, followed by once daily doses in the morning for 4 days.
Study: NCT06426251

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation
Description: Photobiomodulation therapy will be given daily start on the first day after surgery to post operative day 6

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation therapy will be given daily start on the first day after surgery to post operative day 6
Study: NCT05275075

Intervention type: OTHER
Intervention: Pancreatic cancer microRNA and messenger RNA expression.
Description: Tumor specimens from pancreatic patients will be analyzed for markers associated with muscle loss.
Study: NCT05823415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laterally Closed Tunnel with CTG
Description: A novel minimally invasive surgical approach laterally closed tunnel technique (LCT) has been recently introduced for the management of isolated gingival recession. The laterally closed tunnel technique ensures predictability by tunneling and mobilization of flap for graft coverage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF with CTG
Description: Gold standard surgical technique
Study: NCT05410613

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: electromagnetic field and a plantar resistance exercise
Description: Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz.~a plantar resistance exercise therapy by the StepIt rocker pedal, the overall exercise program will be to exercise on the pedal with the index leg for 1 min - then rest it for 1min - and to repeat this 10 times (20 minutes). This regime will be done twice daily (e.g .morning and evening).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: Pulsed electromagnetic field therapy applied with intensity equal to 3mt and frequency of magnetic field impulses equal to 4 Hz

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: standard general advice according to hospital protocol
Study: NCT05326490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB-201
Description: PB-201: 100 mg each time, orally in the morning and evening respectively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PB-201 matched placebo
Description: PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin hydrochloride
Description: The dosage and administration of metformin hydrochloride remain unchanged before screening
Study: NCT06268171

Intervention type: OTHER
Intervention: ultrasound measurement of the cross-sectional area of the rectus femoris
Description: ultrasound measurement of the cross-sectional area of the rectus femoris at D-1 and D+3, +7 , +14
Study: NCT04747834

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MICOR-304
Description: The MICOR-304 offers a mechanical approach to lens fragmentation and aspiration which provides an alternative to phacoemulsification with no cavitation, no thermogenic energy in the eye, which can eliminate generation of heat inside the eye while maintaining the same minimally invasive surgical approach through a small clear-cornea 2.5 mm incision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MICOR-304
Description: The MICOR-304 offers a mechanical approach to lens fragmentation and aspiration which provides an alternative to phacoemulsification with no cavitation, no thermogenic energy in the eye, which can eliminate generation of heat inside the eye while maintaining the same minimally invasive surgical approach through a small clear-cornea 2.5 mm incision.